Ipsen Expands Existing US Base through Acquisitions Worth $458 Million
By The PharmaDeals Team
Pharma Deals Review: Vol 2008 Issue 97 (Table of Contents)
Published: 6 Jun-2008
DOI: 10.3833/pdr.v2008.i97.169 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
French speciality pharma Ipsen, whose targeted therapeutic areas are oncology, endocrinology and neuromuscular disorders, is acquiring a fully fledged US presence by acquiring Octagen, Tercica and the US subsidiary of the UK's Vernalis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS